#United States #New York #Gross Law Firm #Pacira BioSciences #PCRX

Pacira BioSciences Shareholders: Important Deadline Ahead

The Gross Law Firm has recently communicated a crucial notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). If you've purchased shares during a specified period, you are urged to take action regarding a lead plaintiff appointment concerning an important class action lawsuit.

Key Details of the Class Action

Class Period

The class action covers shareholders who acquired shares of PCRX between August 2, 2023, and August 8, 2024. This timeline is critical for those aiming to register for potential recovery in light of significant developments concerning the company's patents.

The Allegations

A substantial claim has unfolded after Pacira’s announcement on August 9, 2024, revealing that its U.S. Patent No. 11,033,495, related to its product Exparel, was deemed invalid by the court. This patent is integral to Pacira’s operations, contributing to around 80% of its revenue. The judicial decision not only affects the patent’s validity but has also raised concerns about other patents held by the company. Analysts have pointed out that the ruling could enable competitors to enter the market with generic alternatives, exacerbating existing challenges for Pacira.

The immediate impact on Pacira stock was stark. Following the announcement, the stock plummeted from $22.36 to a low of $11.70 in just a day, translating to a staggering decline of over 47%.

Why is This Important?

For shareholders, this situation represents a potentially significant financial risk. The Gross Law Firm is encouraging those who purchased shares during the class period to consider their legal options. Registration for the class action is essential, as being part of the action may allow for possible recovery of losses sustained due to the misleading information regarding the patent's validity.

Important Deadlines

The deadline to register as a lead plaintiff for this case is set for March 14, 2025. Shareholders should act promptly to secure their part in the process.

Next Steps for Shareholders

To register as a shareholder, you will gain access to portfolio monitoring tools that will keep you informed regarding the case's lifecycle. There are no fees or obligations associated with registering. Detailed instructions can be found on the Gross Law Firm's website, and interested parties are encouraged to follow up urgently to protect their interests.

About the Gross Law Firm

The Gross Law Firm prides itself on being a nationally recognized entity specializing in class action lawsuits. Their commitment is to protect the rights of investors adversely impacted by corporate misconduct. Providing a platform for recovery is a critical aspect of their mission, especially in cases where false statements or omissions contributed to inflated stock values.

Contact Information

For further inquiries, shareholders are directed to contact the Gross Law Firm directly.

• - Address: 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

This alert serves as a reminder for shareholders to act without delay in order to ensure that they are fully informed and properly represented in the proceedings. With the complexities surrounding the recent patent invalidation, understanding your rights as an investor in Pacira BioSciences is more crucial than ever.